PubRank

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)

Clinical Trial ID NCT02125461

PubWeight™ 16.55‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02125461

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015 1.18
2 Antibodies to watch in 2016. MAbs 2015 1.17
3 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
4 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
5 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
6 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
7 Cancer stem cell plasticity and tumor hierarchy. World J Stem Cells 2015 0.96
8 Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol 2016 0.96
9 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
10 New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015 0.89
11 A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736. Transl Lung Cancer Res 2014 0.81
12 Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016 0.81
13 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
14 Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 2015 0.80
15 The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol 2015 0.79
16 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
17 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016 0.77
18 Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. Nat Rev Clin Oncol 2015 0.76
19 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
Next 100